Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults
2025Frontiers in ImmunologyJournalOpen access
10.3389/fimmu.2025.1658549Full text1 citations